Grant of Share Options
("Renalytix" or the "Company")
Grant of Share Options
|
Position |
Options granted |
|
|
|
|
Chief Executive Officer |
875,017 |
|
Chief Financial Officer |
575,160 |
|
Chief Technology Officer |
352,902 |
|
Non-Executive Director |
190,000 |
The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of
All the Share Options bar those granted to
The Share Options granted to
The issue of the Share Options to
For further information, please contact:
|
|
|
Via Walbrook PR |
|
|
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
Tel: 020 7597 4000 |
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|
|
|
|
|
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX technology platform to introduce novel laboratory developed and FDA approved tests to enable risk assessment and appropriate care management in adult patients with type 2 diabetes and early-stage CKD. By gaining early visibility into risk for progressive decline in kidney function, and an understanding of associated actionable insights, patients and health care providers may benefit from improved outcomes and decreased costs. For more information, visit our Company website at www.renalytix.com and our product website at www.kidneyintelx.com.
About KidneyIntelX™
KidneyIntelX™ is a laboratory developed test demonstrated to be a reliable, bioprognostic™ methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio - and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). KidneyIntelX has received Breakthrough Device Designation from the
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
|
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Chief Executive Officer |
|||
b)
|
Initial notification /Amendment
|
Initial notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
|
|
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04 |
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
875,017 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
875,017 |
||||
|
|
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
|
|||
f)
|
Place of the transaction
|
Outside of trading venue - off market |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
|
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Chief Financial Officer |
|||
b)
|
Initial notification /Amendment
|
Initial notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
|
|
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04 |
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
575,160 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
575,160 |
||||
|
|
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
|
|||
f)
|
Place of the transaction
|
Outside of trading venue - off market |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
|
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Chief Technology Officer |
|||
b)
|
Initial notification /Amendment
|
Initial notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
|
|
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04 |
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
352,902 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
352,902 |
||||
|
|
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
|
|||
f)
|
Place of the transaction
|
Outside of trading venue - off market |
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
a)
|
|
|
|||
2
|
Reason for the notification
|
||||
a)
|
Position/status
|
Non-Executive Director |
|||
b)
|
Initial notification /Amendment
|
Initial notification |
|||
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
a)
|
|
|
|||
b)
|
LEI
|
213800NTOH3FK3WER551 |
|||
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
a)
|
Description of the financial instrument, type of instrument |
Options over ordinary shares of |
|||
|
|
||||
Identification code |
GB00BYWL4Y04 |
||||
|
|
||||
b)
|
Nature of the transaction
|
Grant of options over shares |
|||
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
190,000 |
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
||||
- Aggregated volume |
190,000 |
||||
|
|
||||
- Price |
|
||||
|
|
||||
e)
|
Date of the transaction
|
|
|||
f)
|
Place of the transaction
|
Outside of trading venue - off market |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the